Arkolith/Insider Trading/ITOS/Form 4

Gall Matthew

Chief Financial OfficeriTeos Therapeutics, Inc. (ITOS) · full profile →Form 4 · filed Aug 29, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
1 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 29, 2025Tender(U)89K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 29, 2025Disposed to issuer(D)9K——0
Aug 29, 2025Disposed to issuer(D)252K——0
Aug 29, 2025Disposed to issuer(D)8K——0
Aug 29, 2025Disposed to issuer(D)42K——0
Aug 29, 2025Disposed to issuer(D)136K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-112236) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML